In a nutshell This study compared the ability of two drugs, ganitumab and conatumumab, to treat patients with metastatic colorectal cancer when added to chemotherapy. Some background Cancer cells express various structures on their surface (called receptors) that may stimulate growth and help avoid destruction by the immune system. Drugs that...
Read MoreCurrent treatment status-Undergoing active treatment-No response Posts on Medivizor
Cabazitaxel works better than mitoxantrone as treatment for metastatic prostate cancer.
In a nutshell This study compared the effect of two chemotherapy drugs used in the treatment of metastatic prostate cancer. Survival rates and pain relief were compared with cabazitaxel (jevtana) or mitoxantrone (novantrone) therapy. Some background Testosterone, the main male sex hormone, facilitates in the growth of...
Read MoreThe effect of cabazitaxel and prednisone in the treatment of metastatic castration resistant prostate cancer
In a nutshell This study looked at the effect, and specifically drug related toxicities, of cabazitaxel (jevtana) plus prednisone treatment in metastatic prostate cancer patients. Some background Prostate cancer grows in response to the hormone testosterone. In order to reduce the effect of testosterone, castration is the mainstay of advanced...
Read MorePhase II clinical trial testing the safety and efficacy of adding entinostat to exemestane therapy in hormone-resistant breast cancer patients
In a nutshell This phase II clinical trial tested whether a new drug, entinostat, can work in concert with exemestane (a hormone therapy drug), to fight breast cancer that no longer responds to hormone therapy alone. Some background Some breast cancers need estrogen (a female sex hormone) to grow. These breast cancer cells respond to estrogen via...
Read MorePanitumumab combined with irinotecan as a treatment for metastatic colorecatal cancer without KRAS mutations
In a nutshell This study looks at the use of panitumumab and irinotecan as a combination treatment in patients with KRAS wild-type (non-mutated) metastatic colorectal cancer which has continued to progress while on standard chemotherapy (oxaliplatin, fluoropyrimidines, irinotecan, bevacizumab). Some background Cancer cells can have...
Read MorePhase III clinical trial for Trametinib shows improved survival in metastatic melanoma patients with BRAF mutations
In a nutshell This study presents the results of a phase III clinical trial evaluating the efficacy and safety of the drug trametinib for the treatment of metastatic melanoma patients with BRAF mutations. Some background BRAF is a protein from a chain of proteins in the cell called the MAP kinase pathway. These play a role in cell division and...
Read MoreBosutinib: a new drug that increases progression free survival in patients with locally advanced or metastatic breast cancer
In a nutshell This paper presents the results of a clinical study which looked at the use of a new drug called Bosutinib (Bosulif) for the treatment of breast cancers diagnosed as being stage III or IV. In patients previously treated with chemotherapy, Bosutinib showed promising efficacy in delaying cancer progression. Some background Locally...
Read MoreRegorafenib is a new drug for the treatment of metastatic colorectal cancer after failure of previous therapies
In a nutshell The present study evaluated the efficacy of a new drug, Regorafenib, for the treatment of refractory (progressing despite several lines of treatment) metastatic colorectal cancer (mCRC). Some background Many of the patients with colorectal cancer do not present any symptoms in the early stages of the disease so the cancer...
Read MoreRadiofrequency ablation may slow down the progression of metastatic colorectal cancer
In a nutshell This report aimed to establish if radiofrequency ablation (RFA) of liver metastases originating from colorectal cancer (CRC) provides any benefits to patients with Stage IV of the disease. Main result: RFA extends progression-free survival by 7 months. Some background RFA is a medical procedure for treating patients with small tumors...
Read MoreMetastatic colorectal cancer: the benefit of combining cetuximab with chemotherapy
In a nutshell The present study investigated if patients with spread colorectal cancer that have mutations in the KRAS gene benefit from Cetuximab treatment. Some background Cancer that originates in the colon or rectum (parts of the intestine) is called colorectal cancer (CRC). If the cancer has spread from its original location, beyond the...
Read MoreWell-timed Docetaxel (Taxotere) therapy offers the best results in treating hormone-refractory prostate cancer
In a nutshell This article reports the results of recent studies involving the drug Docetaxel (Taxotere). The drug did not improve overall survival when added to androgen-deprivation therapy. Smaller doses given in shorter treatment cycles were found to be easier to tolerate and more effective. Some background Prostate cancer grows in...
Read MoreCombining Bevacizumab with chemotherapy for advanced colorectal cancer: efficacy evaluation
In a nutshell The present study evaluated whether combining Bevacizumab (Avastin) with chemotherapy for patients with stage IV (metastatic) colorectal cancer (CRC) has any benefits in the terms of survival and quality of life. Main findings: Bevacizumab may be beneficial only as part of certain chemotherapy regimens. Some...
Read More
